Stifel analyst Paul Matteis reiterated a Buy rating and $44.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE), following Q4 update ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE